Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Anbalagan has led end-to-end product development programs from concept to commercialization, with a strong focus on regulatory compliance, process scalability, and manufacturing readiness
The facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
The move signals a major expansion in access to next-generation weight-loss therapies
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Subscribe To Our Newsletter & Stay Updated
